Global Metformin Drugs Market Size By Type (50 Tablets, 100 Tablets), By Application (Hospital, Drugs Stores), By Region, And Segment Forecasts, 2023 to 2032

The Global Metformin Drugs Market was valued at USD 4.9 billion in 2023 and is projected to reach USD 8.2 billion by 2031, growing at a CAGR of 6.4% during the forecast period from 2023 to 2031. The market is witnessing significant growth due to the rising global prevalence of type 2 diabetes, favorable government health initiatives, and increasing awareness of metabolic disorders. Metformin, being the first-line therapy for type 2 diabetes, is extensively prescribed due to its proven efficacy, low cost, and favorable safety profile. Furthermore, research into metformin's potential in managing conditions such as polycystic ovary syndrome (PCOS), obesity, and even anti-aging is expected to expand its application base and market potential.

Drivers:

Rising Prevalence of Type 2 Diabetes

The global incidence of type 2 diabetes continues to rise due to sedentary lifestyles, unhealthy diets, and increasing obesity rates. Metformin remains the foundational treatment, driving consistent demand across all regions.

Expanding Geriatric Population

An aging population contributes to a higher prevalence of chronic diseases, including diabetes and metabolic disorders. The geriatric demographic is particularly dependent on effective and well-tolerated therapies like metformin.

Growing Use in Adjunct Therapies

Metformin is increasingly used in combination therapies with SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists, enhancing treatment outcomes and boosting its market share.

Restraints:

Side Effects and Gastrointestinal Intolerance

Despite its advantages, metformin can cause gastrointestinal issues such as diarrhea and nausea, which may lead to poor patient adherence.

Regulatory and Supply Chain Constraints

Stringent regulatory scrutiny over pharmaceutical manufacturing and disruptions in the supply chain—especially during global crises like COVID-19—pose risks to the metformin drug supply.

Opportunity:

Repurposing of Metformin for Non-Diabetic Conditions

Metformin’s promising potential in oncology, anti-aging, and cardiovascular applications opens up new market segments and revenue streams for pharmaceutical companies.

Rising Healthcare Access in Emerging Economies

Developing regions in Asia-Pacific, Latin America, and Africa are witnessing improved healthcare infrastructure and increasing awareness, creating untapped growth opportunities for metformin drugs.

Market by System Type Insights:

Based on formulation type, Extended-Release (ER) Metformin emerged as the fastest-growing segment in 2023. While Immediate-Release (IR) Metformin continues to dominate in terms of volume due to its affordability and global availability, ER formulations are gaining traction for their improved tolerability and adherence, particularly in elderly patients and those with gastrointestinal sensitivities.

Market by End-use Insights:

Hospitals and Clinics remained the leading end-use segment in 2023, accounting for over 45% of total revenues. Their dominance is driven by the high number of initial diagnoses and patient follow-ups that lead to long-term metformin prescriptions. Retail Pharmacies are also growing due to the OTC availability of some formulations in select regions and the increasing trend of self-medication in mild prediabetic cases.

Market by Regional Insights:

North America held the largest share of the global metformin drugs market in 2023, driven by high diabetes prevalence, supportive insurance coverage, and robust healthcare systems. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period, owing to the region's vast diabetic population, increasing healthcare access, and growing investment in generic pharmaceutical manufacturing in countries like India and China.

Competitive Scenario:

Key players in the global metformin drugs market include Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, Sun Pharmaceutical Industries Ltd., Novo Nordisk A/S, Sanofi, Apotex Inc., Lupin Limited, Aurobindo Pharma, and Mylan N.V. Companies are actively pursuing regulatory approvals, R&D for extended applications, and strategic partnerships to expand their market footprint. For instance:

In 2024, Merck announced a clinical trial to evaluate metformin’s efficacy in age-related diseases.

Teva Pharmaceuticals launched a co-formulated metformin-SGLT2 inhibitor tablet in key markets in 2023.

Lupin Limited expanded its metformin production facility in India to cater to rising global demand.

Scope of Work – Global Metformin Drugs Market

Key Market Developments:

2023: Sun Pharmaceutical launched an improved gastrointestinal-friendly extended-release metformin product in the U.S. market.

2024: Novo Nordisk collaborated with a digital health firm to pair metformin therapy with continuous glucose monitoring devices for better patient outcomes.

2025: Apotex received regulatory clearance to distribute metformin in new African markets, tapping into unmet needs in low-income regions.

FAQs:

What is the current market size of the Global Metformin Drugs Market?

The market was valued at USD 4.9 billion in 2023.

What is the major growth driver of the Global Metformin Drugs Market?

The increasing prevalence of type 2 diabetes globally is the key growth driver.

Which is the largest region during the forecast period in the Global Metformin Drugs Market?

North America held the largest market share in 2023, while Asia-Pacific is expected to grow fastest.

Which segment accounted for the largest market share in the Global Metformin Drugs Market?

Immediate-Release Metformin held the largest share in 2023, though Extended-Release is growing rapidly.

Who are the key market players in the Global Metformin Drugs Market?

Major players include Merck & Co., Teva Pharmaceuticals, Sun Pharmaceutical, Lupin Limited, and Novo Nordisk.